Publication

Article

Oncology & Biotech News

February 2012
Volume6
Issue 2

Investigational Treatments for Multiple Myeloma

Author(s):

A closer look at 2 investigational agents, carlfilzomib and pomalidomide, that were featured at the 53rd American Society of Hematology annual meeting.

Paul G. Richardson, MD

Carlfilzomib

A number of presentations at ASH focused on carlfilzomib, a second-generation proteasome inhibitor designed to improve upon the efficacy of bortezomib with less peripheral neuropathy. One of the studies that stood out was a phase I/II trial showing that carlfilzomib, lenalidomide, and lowdose dexamethasone (CRd) was highly active and well-tolerated in patients with newly diagnosed multiple myeloma, achieving rapid responses. The study included 53 patients who received CRd in 28-day cycles with a carfilzomib dose of either 20 mg/m2 (n = 4), 27 mg/m2 (n = 13), or 36 mg/m2 (n = 36).

The partial response (≥50% disease reduction) rate was 94% following completion of at least 1 cycle and 100% after at least 4 cycles. All patients completing ≥12 cycles achieved very good partial response, defined as a 90% disease reduction. The combination treatment was welltolerated, with no reported grade 3 or 4 peripheral neuropathy.

Pomalidomide

Several oral presentations at ASH focused on pomalidomide. A phase I/II study examined pomalidomide in combination with cyclophosphamide and prednisone in patients with relapsed/ refractory multiple myeloma. In the phase II part of the study, 66% of the 29 evaluable patients achieved at least partial response. Among lenalidomide- refractory patients, 73% achieved at least partial response. The most common severe side effect was neutropenia, seen in 40% of patients. Other side effects were minimal.

A second phase I/II study compared pomalidomide alone versus pomalidomide plus low-dose dexamethasone in relapsed/refractory multiple myeloma Among the 221 patients enrolled in the phase II part of the trial, partial response was achieved in 34% treated with pomalidomide plus dexamethasone versus 13% in the pomalidomide alone arm. Median progression-free survival was 4.7 months and 2.7 months, respectively, for the 2 arms. Median overall survival was 16.9 months and 14 months, respectively. The most frequently reported severe side effect was neutropenia.

Jakubowiak AJ, Dytfeld D, Jagannath S, et al. Final results of a frontline phase I/II study of carfilzomib, lenalidomide, and low-dose dexamethasone in multiple myeloma. Blood. (ASH Annual Meeting Abstracts) 2011;118(21, abstr 631).

Palumbo A. Larocca A, Carella AM, et al. A phase I/II study of pomalidomide-cyclophosphamide-prednisone in patients with multiple myeloma relapsed/refractory to lenalidomide. Blood. (ASH Annual Meeting Abstracts) 2011;118(21, abstr 632).

Richardson PG, Siegel DS, Vij R, et al. Randomized, open label phase I/II study of pomalidomide alone or in combination with low-dose dexamethasone in patients with relapsed and refractory multiple myeloma who have received prior treatment that includes lenalidomide and bortezomib: phase II results. Blood. (ASH Annual Meet- Paul G. Richardson, MD ing Abstracts) 2011;118(21, abstr 634).

Related Videos
Minoo Battiwalla, MD, MS
Farrukh Awan, MD, discusses treatment considerations with the use of pirtobrutinib in previously treated patients with hematologic malignancies.
Douglas W. Sborov, MD, MS
Meletios (Thanos) Dimopoulos, MD, professor, therapeutics, Hematology Oncology, National and Kapodistrian University of Athens School of Medicine
Michel Delforge, MD, PhD
Francine Foss, MD
Ashraf Z. Badros, MBCHB, professor, medicine, Medical Oncology, Hematology Oncology, University of Maryland Medical System
David C. Fisher, MD
Binod Dhakal, MD
Michel Delforge, MD, PhD, professor, Faculty of Medicine, Department of Hematology, director, member, Leuven Cancer Institute, member, Senior Academic Staff, Council of the Faculty of Medicine, Council of the Department of Oncology, University Hospital Leuven, University of Leuven